Davide Capodanno/LinkedIn
Jan 11, 2026, 03:54
DAPT De-escalation After PCI․ Where Do We Stand Today?
Davide Capodanno, Full Professor of Cardiology at the University of Catania, shared on X:
“ DAPT after PCI remains essential, but balancing ischemic protection and bleeding risk is challenging. Over the past decade, trials have supported DAPT de-escalation—via dose reduction, drug withdrawal, or switching agents—to reduce bleeding without compromising ischemic outcomes in selected patients. Evidence for escalation is more limited. We wrote this review to summarize current data and ongoing studies. ”
Title: Dual Antiplatelet Therapy Escalation and De-escalation
Authors: Antonio Greco, Giacinto Di Leo, Simone Finocchiaro, Antonino Imbesi, Davide Capodanno
Read full article here.
Stay updated with Hemostasis Today.
-
Apr 11, 2026, 13:51David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
-
Apr 11, 2026, 13:47Samrawit Terefe: O Negative Blood Is the Universal Donor With Extreme Scarcity
-
Apr 11, 2026, 13:39Dheeraj Garg: Rethinking Cardiovascular Disease – A Cardiologist’s Perspective
-
Apr 11, 2026, 13:37Kushal Bhatia: Is The 4.5-Hour Thrombolysis Window Officially Outdated?
-
Apr 11, 2026, 13:35William Aird: Why Did Mammalian Red Blood Cells Give Up Their Nucleus?
-
Apr 11, 2026, 13:30Ken Kuang: Gravity Is Constant, But Your Vein Health Doesn’t Have to Be
-
Apr 11, 2026, 13:21Mascha Kern: Measuring Gender’s Role in Stroke and Migraine
-
Apr 11, 2026, 13:10Danique Steeghs: Key Findings from a Microfluidic Chemiluminescent Thrombin Generation Assay
-
Apr 11, 2026, 13:06Shanvi Mahi: A Validated Tool to Explore Lived Experiences After Stroke Rehabilitation